Abstract
Background: An accurate assessment of septic patients at risk for poor clinical outcomes is challenging for clinicians in the emergency department (ED).

Objectives: We aimed to evaluate the prognostic value of procalcitonin (PCT) in septic patients in the ED for predicting death.

Results: In a retrospective study, 188 septic patients (median age 63 [IQR 51–80]) of two French university hospitals were included. Patients who deceased within 30 days (20%, n = 37) presented higher PCT value at admission (median 34.0 µg/L [5.0–71.9]) in comparison with the survivals (median 6.4 µg/L [4.1–13.1], p = 0.0005). ROC curve analysis indicated a moderate AUC of 0.686 [95% CI 0.613–0.752] and an optimal PCT threshold value at 32.5 [95% CI 21.8–43.3] µg/L that was associated with a 51% [34–67] sensitivity, a 96% [90–98] specificity, a 73% [52–88] positive predictive value, and a 89% [83–93] negative predictive value for death. Only 26 patients (14%) had PCT values above this threshold (19 in the deceased group vs 7 in survival group, p < 0.0001). By multivariate analysis, only three variables remained significantly predictive of the death: personal history of cardiovascular disease (OR 3.1 [1.0–9.4], p = 0.046), the presence of severe sepsis/septic shock in the ER (OR 4.4 [1.3–12.3], p = 0.013), and a PCT level >32.5 µg/L (OR 36.0 [10.0–128.4], p < 0.0001). Similar results were obtained when considering the combined outcome death and/or admission in ICU.

Conclusion: Elevated value of PCT at admission has moderate accuracy to identify poor outcome in ED septic patients in daily practice.

Keywords: Procalcitonin, Sepsis, Emergency department, Prognostic

Background
Sepsis is a life-threatening condition that arises when the host’s response to an infection injures its own tissues and organs [1]. The accurate identification of sepsis is one of the main challenges in emergency medicine. Despite advances in antibiotic therapy and modern life support, fatality rate of patients with sepsis has remained high worldwide (>30%) [1, 2].

Early identification of patients at high risk of dying from sepsis may help initiate rapid and appropriate therapeutic interventions. However, signs of organ dysfunction may not be obvious for the physician’s at the time of presentation [3]. Thus, an accurate assessment of patients at risk for poor clinical outcomes is challenging for clinicians in the emergency department (ED).

Procalcitonin (PCT), the pro-hormone of calcitonin, is synthesized by thyroid cells. During sepsis, many tissues and immune cells become able to secrete PCT. The enhanced specificity of PCT along with the publication of numerous clinical and interventional studies has contributed to the growing interest and implementation of PCT in the ED as a biomarker of the systemic host response to bacterial invasion [3, 4]. Several studies have demonstrated that PCT may confer prognostic information in PAC [5] and in sepsis [6], and some have suggested the...
same in an ED. Recently, PCT-based sepsis diagnosis was demonstrated to be more reliable and discriminat-
ing than clinical sepsis diagnosis [7]. Furthermore, lact-
tate and PCT might be complementary biomarkers for
the risk stratification of ED patients evaluation [3]. Thus,
PCT might be a good candidate to accurately identify ED
septic patients with poor outcome.

Therefore, we aimed to evaluate the prognostic value of
PCT in septic patients in the ED.

Patients and methods
It was a retrospective study, which took place in the EDs
of two university hospitals (Tenon hospital in Paris and
Rouen), from July 2011 to December 2011. Both were
urban adult ED and teaching hospitals with, respec-
tively, 45,000 and 82,000 annual new patient attendances.
Because of the observational design of the study, the ethi-
cal committee (CPP Ile-de-France Paris VI, Paris, France)
authorized a waiver of informed consent. In these two
hospitals, PCT is widely used by physicians’ in charge, for
patients with suspected or confirmed infections, espe-
cially in suspicion of lower respiratory tract infections.
However, no real guideline is associated with the result
of PCT.

Studied population
Patients ≥18 years old were included if they presented
with a confirmed diagnosis of infection, and had a PCT
measurement blood sampled routinely performed in the
ED with a level ≥2 µg/L. This PCT threshold was chosen
upon previous studies observations, where ED patients
with PCT ≥2 µg/L were suggested as having a sepsis and
high risk of development of organ dysfunction [4, 8]. For
each patient, ED electronic file and recorded admission
data (including initial vital variables, routine biological
data, and admitting diagnosis in ED) were collected, as
well as outcome (discharge, admission to a medical ward
or ICU, in-hospital mortality) and final diagnosis, i.e.,
each patient had a confirmation of sepsis suspected in
the ED (based on all medical charts and available micro-
biological data). The presence of systemic inflamma-
tory response syndrome (SIRS), sepsis, or severe sepsis/
septic shock criteria [9] was also recorded, either at ED
admission or during follow-up. For this study, hyperlac-
tatemia (>2 mmol/L) was used as a severe sepsis criterion
(although not specific) [10]. However, patients with other
causes of high lactate levels were not excluded.

Patients were further categorized according to two dif-
ferent outcomes: death at day 30, or a combined outcome
of death and/or admission to ICU during the follow-up
of day 30.

PCT measurement
In Tenon hospital, PCT concentrations were analyzed
using a sandwich immunoassay based on time-resolved
amplified cryptate emission (TRACE) measurement
(Kryptor analyzer; B.R.A.H.M.S. Thermo Fischer,
Germany). In our laboratory, coefficients of variation (CV)
for PCT were found to be <10 % at 0.28 and 10.8 µg/L.
In Rouen hospital, procalcitonin concentrations were
analyzed using an electrochemiluminescent immunoas-
say (ELECSYS BRAHMS procalcitonin, Hennigsdorf,
Germany), performed on a Cobas e601 analyzer (Roche
Diagnostics, Meylan, France). In our laboratories, coef-
ficients of variation for procalcitonin were <4 % at 2
concentrations during the study period. Both methods
are correlated [11]. In our laboratories, correlation coef-
ficient was $R^2 = 0.964$ (slope: 1.04, intercept: −0.73),
and we observed 96.4 % of concordance between the
two methods (data not shown). Median bias observed
between the two methods was 11 %, which is acceptable
[12]. The upper reference limit (URL) announced by the
manufacturer was 0.046 µg/L.

Statistical analysis
Results were expressed as medians [interquartile range,
IQR] for continuous variables and numbers (percent-
age) for discrete variables. Data were compared using
the Kruskal–Wallis test for continuous variables, and the
Chi-square for differences in frequencies.

Receiver operating characteristic (ROC) analysis was
performed in order to determine the best thresholds
for PCT (or the combination of PCT + lactate after log
transformation) which would be predictive of the out-
come. Because of the possible impact of sample size on
threshold value, a bootstrap analysis (1000 random sam-
pies with replacement) was performed to obtain a cal-
culation of the optimal threshold of PCT and its 95 %
confidence interval [13]. We assessed the sensitivity and
specificity, positive (PPV) and negative predictive value
(NPV) (all with their 95 % confidence intervals [95 % CI],
calculated with the Wilson's score with correction of con-
tinuity) for thresholds.

As the ROC curve is recognized to be potentially insen-
sitive, the net reclassification index (NRI) method was
used, as described [13]. For tests with binary outcomes,
NRI is the same as the gain in certainty of the first test
minus the gain in certainty of the second test, or alterna-
tively stated, the differences in the sum of the sensitivity
and specificity:

\[
NRI_{\text{second test vs first test}} = (\text{Sensitivity} + \text{Specificity})_{\text{second test}} - (\text{Sensitivity} + \text{Specificity})_{\text{first test}}
\]
Since NRI is a powerful statistical tool, significant results might only have a poor clinical impact. In order to illustrate the improvement given by lactate in association with PCT, we provide a reclassification table that enables us to quantify the benefit of the association in terms of number of patients correctly reclassified. Furthermore, the reclassification table offers a practical representation of both the relationship between false positive and false negative, and the magnitude of the gain of predictability in quantitative terms (number of patients).

We further evaluated PCT and lactate combination using the best linear combination (BLC) method [14]. Briefly, this method relies on the creation of a formula in which PCT and lactate are moderated by their coefficient of covariance in the studied population. The obtained combination gives a score for each patient that can be studied as a biomarker by itself and submitted to ROC analysis and logistic regression.

A forward logistic regression was performed to assess variables associated with outcome. For this analysis, PCT levels were evaluated as categorical variables based on the optimum cutoff point previously determined by ROC curve. We adopted a conservative approach and only included significant preoperative variables in the univariate analysis (p value of entry <0.10). The discriminative power of the logistic regression was evaluated by the c-statistic (concordance index) and the goodness of fit of the model by the Hosmer–Lemeshow test.

The results were analyzed using Med Calc 3.4.2.0 for Windows (MedCalc Software, Mariakerke, Belgium). All tests were two-tailed. A p value <0.05 was considered to be statistically significant.

**Results**

Main characteristics of the studied population (n = 188) are presented in Table 1. As expected, main sources of sepsis were pulmonary and urinary infections. Forty-three percent of patients had a severe sepsis/septic shock, and 28% were transferred in ICU. Briefly, patients who deceased within 30 days (20%; n = 37) were older, presented an initial higher cardiac rate and respiratory rate, had more comorbidities, had more frequently severe sepsis or septic shock, and presented higher lactate levels than survivors. Of note, there was no difference in age values between recruitment sites (p = 0.337). Ninety-one percent of patients were admitted to the hospital.

Patients with severe sepsis/septic shock had higher cardiac rate (110 [94–125] vs. 96 [84–110], p = 0.001) and respiratory rate (30 [24–38] vs. 20 [18–26], p = 0.003), higher lactate (2.4 [1.7–3.6] vs. 1.9 [1.5–2.8] mmol/L, p = 0.053), and lower diastolic blood pressure (62 [51–75] vs. 76 [64–84], p < 0.0001), lower systolic blood pressure (99 [88–119] vs. 129 [107–148], p < 0.0001), and higher SpO2 (96 [94–98] vs. 94 [91–98] %, p = 0.041), than those without severe sepsis/septic shock. Furthermore, patients admitted to ICU were younger (60 [49–81] vs. 69 [52–83] years, p = 0.011), had lower diastolic blood pressure (62 [50–76] vs. 73 [61–81] mm Hg, p = 0.005), lower systolic blood pressure (100 [90–126] vs. 120 [100–139] mm Hg, p = 0.005), higher respiratory rate (32 [27–39] vs. 24 [20–32], p = 0.010), higher lactate (2.5 [2.0–3.4] vs. 2.1 [1.5–2.9] mmol/L, p = 0.039), and presented more frequently severe sepsis/septic shock (68 vs. 38 %, p = 0.001), than patients not admitted to ICU.

The median PCT value was higher in the deceased group (median [interquartile range, IQR] (34.0 µg/L [5.0–71.9]) in comparison with the survivals (6.4 [4.1–13.1] µg/L, p = 0.0005) (Fig. 1). However, PCT values were not significantly higher in patients admitted to ICU in comparison with the others (9.6 [4.1–18.2] vs. 6.1 [3.9–14.1] µg/L, p = 0.145); same observation was done when comparing PCT values between patients with severe sepsis/septic shock versus others (8.6 [4.9–23.7] vs. 6.2 [3.6–12.3] µg/L, p = 0.064). Of note, there was no difference in PCT values between recruitment sites (p = 0.674).

**ROC analysis**

The ROC curve analysis indicated a moderate accuracy, with an AUC at 0.686 [95 % CI 0.613–0.752] (p = 0.002) for PCT to predict 30-day mortality (Fig. 2a). Defined by the ROC curve, the optimal threshold value was 32.5 [95 % CI 21.8–43.3] µg/L and was associated with a 51 % [34–67] sensitivity, a 96 % [90–98] specificity, a 73 % [52–88] PPV, and a 89 % [83–93] NPV. Only 26 patients (14 %) had PCT values above this threshold. The proportion of patients with PCT > 32.5 µg/L in the deceased group was significantly higher (51 %, n = 19) than in the survival group (5 %, n = 7) (p < 0.0001). However, the proportion of patients with PCT > 32.5 µg/L in the severe sepsis/septic shock (19 %, n = 16) was not significantly different from the proportion of patients with PCT > 32.5 µg/L in patients without severe sepsis/septic shock (10 %, n = 12) (p = 0.123).

The ROC curve analysis indicated a moderate accuracy for PCT to predict death and/or admission in ICU, with an AUC at 0.644 [0.571–0.712] (p = 0.007), with an optimal threshold value at 9.9 µg/L (Fig. 2b). This threshold was associated with a 54 % [42–65] sensitivity, a 73 % [63–90] specificity, a 70 % [61–78] PPV, and a 57 % [45–68] NPV.

When patients were classified according to PCT categories (arbitrarily defined as PCT < 5 µg/L, PCT between 5 and 19.9 µg/L, PCT between 20 and 31.9 µg/L, and PCT ≥ 32 µg/L), we observed that mortality raised dramatically only in patients with PCT ≥ 32 µg/L, while ICU transfer was not affected by PCT value (Fig. 3).
### Table 1 Characteristics of the studied population

|                                | All patients | Deceased at 30 days | Survival | \( p^* \) |
|--------------------------------|--------------|---------------------|----------|----------|
| **n**                          | 188          | 37                  | 151      | 0.605    |
| Patients of Rouen [n (%)]      | 97 (52)      | 21 (57)             | 76 (50)  |          |
| Patients of Tenon [n (%)]      | 91 (48)      | 16 (43)             | 75 (50)  | vs Tenon |
| Age (years)                    | 63 (51–80)   | 78 (63–83)          | 64 (46–78)| 0.001    |
| Men [n (%)]                    | 101 (54)     | 22 (59)             | 79 (52)  | 0.551    |
| Temperature (°C)               | 38.1 (37.1–39.0) | 38.2 (37.1–39.8) | 38.1 (37.0–38.8) | 0.321    |
| Systolic blood pressure (mmHg) | 113 (96–137) | 113 (93–136)        | 116 (97–137) | 0.524    |
| Diastolic blood pressure (mmHg)| 70 (57–80)   | 65 (52–81)          | 72 (59–80) | 0.260    |
| Cardiac rate, in bpm           | 100 (87–118) | 110 (95–129)        | 99 (85–116) | 0.051    |
| Respiratory rate (RR) (n = 74) | 26 (20–34)   | 32 (29–40)          | 25 (20–32) | 0.009    |
| SpO₂ in %                      | 95.0 (92.5–98.0) | 95.0 (91.0–97.5) | 95.0 (93.0–98.0) | 0.636    |
| **Personal history of:**       |              |                     |          |          |
| Cardiovascular disease [n (%)] | 94 (50)      | 24 (65)             | 70 (46)  | 0.052    |
| Respiratory disease [n (%)]    | 43 (23)      | 13 (35)             | 30 (20)  | 0.063    |
| Other (chronic) [n (%)]        | 51 (27)      | 5 (14)              | 46 (30)  | 0.099    |
| Imunosuppressors, corticoids, or chemotherapy [n (%)] | 29 (15) | 5 (14) | 24 (16) | 0.677    |
| Bacterial infection [n (%)]    | 139 (74)     | 27 (73)             | 112 (74) | 0.159    |
| Pulmonary infection [n (%)]    | 59 (31)      | 7 (19)              | 52 (34)  | 0.085    |
| Urinary infection [n (%)]      | 30 (16)      | 5 (14)              | 25 (17)  | 0.914    |
| Abdominal infection [n (%)]    | 21 (11)      | 7 (19)              | 14 (9)   | 0.169    |
| Skin/tissue infection [n (%)]  | 8 (4)        | 3 (8)               | 5 (3)    | 0.361    |
| Meningitis [n (%)]             | 2 (1)        | 1 (3)               | 1 (1)    | 0.828    |
| Several sitesa                 | 12 (6)       | 1 (3)               | 11 (7)   | 0.526    |
| Other siteb                    | 7 (4)        | 3 (8)               | 4 (3)    | 0.264    |
| Viral infection [n (%)]        | 3 (2)        | 1 (3)               | 2 (1)    | 0.835    |
| Other infection [n (%)]c       | 46 (24)      | 9 (24)              | 37 (25)  | 0.669    |
| Severe sepsis/septic shock [n (%)] | 81 (43)   | 22 (59)            | 59 (39)  | 0.040    |
| Median lactate (mmol/L) (n = 103) | 2.2 (1.5–3.2) | 3.1 (2.2–4.4)  | 2.1 (1.5–2.8) | 0.003    |
| Median white blood cells (G/L) | 12.1 (7.9–18.4) | 12.1 (9.0–17.4) | 12.0 (7.5–18.7) | 0.966    |
| Hospital admission [n (%)]     | 172 (91)     | 33 (89)             | 139 (92) | 0.818    |
| Admission in ICU [n (%)]       | 52 (28)      | 14 (38)             | 38 (25)  | 0.181    |
| Length of hospitalization (days)| 9 (5–14)   | 5 (2–10)            | 10 (6–16) | <0.0001  |

Results are in mean ± SD, median (25th–75th percentile), or number (percentage)

* Between patients deceased and survival

a Mainly pulmonary and urinary concomitant bacterial infection

b Bacterial infection (ENT, blood stream infection from unknown origin)

c Non-bacterial infection (i.e., parasitic, fungic, or mycobacterium infection)

### Analysis of subgroup in patients with available lactate measurement

When considering patients with available lactate measurement \( (n = 103) \), patients with PCT > 32.5 µg/L presented higher median lactate values \( (3.3 \ [1.9–4.3] \ \text{mmol/L}) \), in comparison with patients with lower PCT \( (2.1 \ [1.5–3.0] \ \text{mmol/L}, \ p = 0.0347) \).

When combining PCT and lactate log-transformed values, the ROC curve analysis indicated an AUC at 0.692 \([95\% \ CI \ 0.594–0.780]\) for the prediction of 30-day mortality. This was significantly higher than PCT alone in this subgroup \( (p = 0.020) \). However, sensitivity (50 %) and specificity (96 %) were similar to those obtained with PCT alone. Alternatively, using the BLC method, we obtained the following combination: PCT \((\text{in } \mu\text{g/L}) + 0.025 \times \text{lactate (in mmol/L)}\). This combination gives a score for each patient and was tested in ROC analysis. Unfortunately, it failed to maximize ROC curve \( (\text{AUC} = 0.633 \ [0.533–0.726] \text{ vs. PCT alone, } p = 0.061) \).

Patients with both PCT > 32.5 µg/L and lactate >2.2 mmol/L (i.e., above ROC thresholds) presented the worse outcome if considering death at day 30 \( (p < 0.0001) \).
(Fig. 4). Using these thresholds, a table of contingency was built (Table 2), and NRI was calculated. The NRI was 0.8 % ($p = 0.980$), indicating that patients were not significantly better identified as at risk of death using lactate on top of PCT alone.

When considering the prediction of death and/or admission in ICU, the combination of PCT and lactate indicated an AUC at 0.677 [95% CI 0.578–0.765], which was significantly higher than PCT alone in this subgroup ($p = 0.012$). However, sensitivity (50 %) and specificity (73 %) were similar to those obtained with PCT alone.

**Multivariate analysis**

Multivariate analysis was performed on the entire study group and is presented in Table 3. Three variables remained independently and significantly predictive of death at day 30: previous history of cardiovascular disease, the presence of severe sepsis/septic shock, and a PCT $> 32.5$ µg/L, which remained the strongest predictor of death. If considering prediction of death and/or admission to ICU, a PCT value $> 32.5$ µg/L also remained the strongest independent and significant predictor, with an OR value at 6.4 [2.3–17.9] ($p = 0.0004$), with the presence of severe sepsis/septic shock (OR 4.4 [2.2–8.9]).

If considering prediction of death and/or admission to ICU, the PCT + lactate score remained the only independent and significant predictor of death, with an OR value at 6.0 [95 % CI 1.3–28.5] ($p = 0.024$).

**Discussion**

We aimed to evaluate in the emergency setting the prognostic value of PCT in septic patients. Our results demonstrated that PCT is a potential tool by itself for early identification of ED septic patients with poor outcome (death at day 30). However, its prognostic accuracy is not useful enough, to be used in daily practice.

A recent meta-analysis indicated that elevated PCT concentrations are associated with all-cause mortality in septic patients. However, studies are still lacking to define the optimal cutoff point, especially in ED patients [1]. This previous meta-analysis pointed out the heterogeneity of the results observed in the studies. In the specific field of ED patients, there are few studies that report association of PCT level with mortality [15–17]. Authors present heterogeneity in methodologies (fully automated or semiquantitative assays), in reported cutoffs (from 0.9 to 10 µg/L), and in testing time (day 0, 1 or 5). In addition to these data, the study of Freund et al. [3] indicated, with another fully automated method for PCT (Kryptor...
Brahms), a cutoff at 0.8 µg/L for identification of severe outcome in the ED. Thus, relationship between PCT and prognosis required further study.

To our knowledge, our study is the first to focus on patients with high-PCT values (above 2 µg/L) in emergency septic patients. Our results suggest a moderate relation between PCT level and outcome, in the specific population of septic patients with high PCT. As expected, we find a higher cutoff than previous studies performed in ED [3, 15–17], but we also had a better specificity. In terms of patients’ recruitment, our results should be compared to those of Hur et al. [7] who investigated the diagnostic and prognostic utility of PCT in critically ill patients with suspected sepsis in ED and ICU, for whom sepsis was diagnosed clinically or on PCT concentrations. Thus, our results are in accordance with those of Hur et al. [7], as we found similar PCT values in non-survivors (mean PCT at admission around 32 µg/L).

When considering our ROC curve analysis for death prediction, our results are similar to those of Zhao et al. [18] and to those of Wang et al. [19], but with a higher cutoff. In our population, we observe similar performances with the solely PCT, in comparison with that of Zhao when using MEDS score +PCT [18], or to that of Wang using PCT alone [19]. Wang et al. [19] found a 28-day mortality cutoff at 4.3 µg/L, which is lower than ours, but they included both septic patients and SIRS patients without infection. MEDS score has been suggested as a score system with high ability to predict the 28-day outcome of ED patients with systemic inflammatory response syndrome (SIRS), sepsis, or severe sepsis [20–22]. However, some studies indicated that MEDS score is not suitable for patients with severe sepsis or septic shock [23, 24].

We found that PCT is a moderate predictor of 30-day mortality but also for the prediction of death and/or admission in ICU in confirmed septic ED patients. Our results are in accordance with most of the previous studies [4, 7, 15–18]. However, some studies also failed to demonstrate any prognostic value of PCT [19]. In our septic population, the PCT value for predicting 30-day mortality is higher (32.5 vs 4.3 µg/L), with a better specificity (96 vs 84 %) than previously observed [19]. However, this strategy allows to target a small number of patients in our population (n = 19 deceased patients with severe sepsis in ED).
Furthermore, when considering the ROC curve analysis for the prediction of death and/or admission in ICU, prognostic performances were lower, and we did not find any significant difference in PCT values between patients admitted to ICU versus the others. This latest observation was somehow expected as many other factors (such as comorbidities including dementia, functional status, and bed availability…) are used in the decision to admit a patient in ICU. The weight of biological (as PCT) or physiological data is probably relatively low compared to other variables in the decision of ICU transfer, as reflected by our Fig. 3.

In our subgroup analysis, we did not observe any additional performance when combining lactate to PCT, for the prediction of 30-day mortality or for the prediction of death and/or admission in ICU. This is not in accordance with results obtained by Freund et al. [3], who—in a larger sample of ED patients—considered a combined outcome (death and/or ICU admission and/or terminal patients with therapy limitations). However, our patients

### Table 2 Net reclassification table of patients according to PCT and lactate values

| PCT > 32.5 µg/L | Death at 30 days (n) | Alive (n) | Total (n) |
|-----------------|---------------------|----------|----------|
| PCT and/or lactate above threshold | 11 | 3 | 14 |
| PCT < 32.5 µg/L | 15 | 74 | 89 |
| PCT and lactate below thresholds | 5 | 45 | 50 |
| Total | 26 | 77 | 103 |

NB. This is the practical representation of both the relationship between false positive and false negative (gray zones), and the magnitude of the gain of predictability in quantitative terms (number of patients): here, the strategy PCT + lactates provokes a decrease in false negative (from 15 to 5) but a concomitant increase in false positives (from 3 to 32). The consequence is that sensitivity is improved (from 11/26 = 42.3 % to 21/26 = 80.8 %), but consequently specificity is dramatically decreased (from 74/77 = 96.1 % to 45/77 = 58.4 %)

Thus, the NRI calculation is: NRI = (80.8 + 58.4) − (42.3 + 96.1) = 0.8 %

* 32.5 µg/L for PCT, 2.2 mmol/L for lactate

### Table 3 Univariate and multivariate analysis for independent prediction of death at 30 days

|                          | Univariate analysis | p     | Multivariate analysis | p     |
|--------------------------|---------------------|-------|-----------------------|-------|
|                          | OR [95 % CI]        |       | OR [95 % CI]          |       |
| Age                      | 1.04 [1.01–1.06]    | 0.0015| /                     |       |
| Heart rate               | 1.02 [1.00–1.03]    | 0.047 | /                     |       |
| Personal history of:     |                     |       |                       |       |
| Cardiovascular diseases  | 2.5 [1.1–5.7]       | 0.024 | 3.1 [1.0–9.4]         | 0.0462|
| Respiratory disease      | 2.4 [1.05–5.2]      | 0.036 | /                     |       |
| “Other” chronic diseases | 0.4 [0.1–1.0]       | 0.052 | /                     |       |
| Severe sepsis/septic shock | 2.3 [1.1–4.8]     | 0.027 | 4.0 [1.3–12.3]        | 0.0130|
| PCT > 32.5 µg/L          | 21.7 [8.0–58.8]     | <0.0001| 36.0 [10.0–128.4]     | <0.0001|

As data were partially collected for lactate and respiratory rate, these parameters could not be included in the analysis
with both PCT > 32.5 µg/L and lactate >2.2 mmol/L presented the worst outcome, which suggests the potential complementary role of both biomarkers in identifying very high-risk patients. Unfortunately, using NRI and BLC methods, we failed in finding strong additional information in the association PCT + lactate. This might be because of the small subgroup number of patients and should be specifically investigated in a larger cohort.

Limitations
Some limitations merit consideration in this study. Firstly, this is a bicentric retrospective, non-blind study, including a somehow limited number of patients. Secondly, we did not use severity score systems (MEDS, SOFA, etc.) to compare with, or in addition to PCT. Thirdly, the dynamic changes in biomarkers were not evaluated. Fourthly, we do not have data on previous antibiotic therapy or antibiotics given in the ER or after. Thus, we do not have information on their adequacy. Fifthly, lactate was not measured systematically to all patients. Therefore, this variable could not be fully investigated and included in our multivariate analysis. Finally, two different methods were used to assay PCT. However, the two methods are known to be highly correlated [11, 12], and a minimal bias was observed in our population.

Conclusion
Elevated value of PCT at admission has moderate accuracy to identify poor outcome in ED septic patients. We suggest that the measurement of PCT in ED septic patients should not be routinely performed to assess prognostic information, before other evaluation of its added value in further studies.

Authors’ contributions
NP and PR designed the study and contributed substantially to patients’ recruitment, analysis of data, and drafting the manuscript. CG performed analysis of data and wrote the manuscript. LM, NP, RL, and VA contributed substantially to patients’ recruitment and were actively involved in the acquisition of data. VB and GL performed measurements and contributed substantially to analysis and interpretation of data. All authors read and approved the final manuscript.

Author details
1 Department of Emergency Medicine, Centre Hospitalier universitaire de Rouen, 1 rue de Germont, 76000 Rouen, France. 2 Department of Automated Biological Diagnosis, Hôpitaux Universitaires Paris Centre (HUPC) – Hôpital Cochin, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France. 3 Department of Emergency Medicine, Hôpitaux Universitaires Est Parisien - Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France. 4 Department of Biochemistry and Hormonology, Hôpitaux Universitaires Est Parisien - Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France. 5 Department of Biochemistry, Clinical Biology Institut, Centre Hospitalier universitaire de Rouen, 1 rue de Germont, 76000 Rouen, France. 6 Sorbonne Universités UMPC Université Paris 06, DHU Fighting Aging and Stress (FAST), Paris, France.

Competing interests
The authors declare that they have no competing interests.

Received: 19 October 2015 Accepted: 21 April 2016 Published online: 21 May 2016

References
1. Liu D, Su L, Han G, Yan P, Xie L. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One. 2015;10(11):e0129450.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. 2012. Crit Care Med. 2013;41:580–637.
3. Freund Y, Delerme S, Goulet H, Bernard M, Riou B, Hausfater P. Serum lactate and procalcitonin measurements in emergency room for the diagnosis and risk-stratification of patients with suspected infection. Biomarkers. 2012;17:590–6.
4. Hausfater P, Juillienn G, Madarona-Py B, Hacho-Re J, Bernard M, Riou B. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care. 2007;11:R60.
5. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical risk rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48–58.
6. Garnacho-Montero J, Huici-Moreno ML, Gutiérrez-Pizarroa A, López I, Márquez-Vácaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care. 2014;18:R116.
7. Hur M, Kim H, Lee S, Cristofano F, Magrini L, Marino R, et al. Diagnostic and prognostic utilities of biomarkers combination using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect Dis. 2014;14:224.
8. Meitner M. Procalcitonin—biochemistry and clinical diagnosis. 1st ed. Bremen: UNI-MED; 2010.
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530–8.
10. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M,ANN, D, Angus D, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
11. de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M. Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. Clin Chem. 2009;55:1043–4.
12. Dipaloo M, Guido L, Micca G, Prittalis S, Locatelli M, Motta A, et al. Multi-center comparison of automated procalcitonin immunoassays. Pract Lab Med. 2015;2:2–8.
13. Ray P, Lemanach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology. 2010;112:1023–40.
14. Su QJ, Liu JS. Linear combinations of multiple diagnostic markers. J Am Stat Assoc. 1993;88:1350–5.
15. Yin Q, Liu B, Chen Y, Zhao Y, Li C. The role of soluble thrombomodulin in the risk stratification and prognosis evaluation of septic patients in the emergency department. Thromb Res. 2013;122:471–6.
16. Magrini L, Travaglini F, Marino R, Ferri E, De Berardinis B, Cardelli P, et al. Procalcitonin variations after Emergency Department admission are highly predictive of hospital mortality in patients with acute infectious diseases. Eur Rev Med Pharmacol Sci. 2013;17:133–42.
17. Kenzaki T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, et al. Use of a semi-quantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis. Int J Gen Med. 2012;5:483–8.
18. Zhao Y, Li C, Jia Y. Evaluation of the Mortality in Emergency Department Sepsis score combined with procalcitonin in septic patients. Am J Emerg Med. 2013;31:1086–91.
19. Wang M, Zhang Q, Zhao X, Dong G, Li C. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study. Crit Care. 2014;18:634.
20. Sankoff JD, Goyal M, Gaeski DF, Deitch K, Davis CB, Sabel AL, et al. Validation of the Mortality in Emergency Department Sepsis (MEDS) score in
patients with the systemic inflammatory response syndrome (SIRS). Crit Care Med. 2008;36:421–6.

21. Lee CC, Chen SY, Tsai CL, Wu SC, Chiang WC, Wang JL, et al. Prognostic value of mortality in emergency department sepsis score, procalcitonin, and C-reactive protein in patients with sepsis at the emergency department. Shock. 2008;29:322–7.

22. Chen CC, Chong CF, Liu YL, Chen KC, Wang TL. Risk stratification of severe sepsis patients in the emergency department. Emerg Med J. 2006;23:281–5.

23. Jones AE, Saak K, Kline JA. Performance of the Mortality in Emergency Department Sepsis score for predicting hospital mortality among patients with severe sepsis and septic shock. Am J Emerg Med. 2008;26:689–92.

24. Nguyen HB, Banta JE, Cho TW, Van Ginkel C, Burroughs K, Wittlake WA, et al. Mortality predictions using current physiologic scoring systems in patients meeting criteria for early goal-directed therapy and the severe sepsis resuscitation bundle. Shock. 2008;30:23–8.